PMID- 36131299
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220924
IS  - 2522-5782 (Electronic)
IS  - 2522-5782 (Linking)
VI  - 4
IP  - 1
DP  - 2022 Sep 22
TI  - Medical cannabis authorization patterns, safety, and associated effects in older 
      adults.
PG  - 50
LID - 10.1186/s42238-022-00158-5 [doi]
LID - 50
AB  - BACKGROUND: Use of medical cannabis is increasing among older adults. However, 
      few investigations have examined cannabis use in this population. METHODS: We 
      assessed the authorization patterns, safety, and effects of medical cannabis in a 
      sub-analysis of 201 older adults (aged >/= 65 years) who completed a 3-month 
      follow-up during this observational study of patients who were legally authorized 
      a medical cannabis product (N = 67). Cannabis authorization patterns, adverse 
      events (AEs), Edmonton Symptom Assessment Scale-revised (ESAS-r), and Brief Pain 
      Inventory Short Form (BPI-SF) data were collected. RESULTS: The most common 
      symptoms for which medical cannabis was authorized were pain (159, 85.0%) and 
      insomnia (9, 4.8%). At baseline and at the 3-month follow-up, cannabidiol 
      (CBD)-dominant products were authorized most frequently (99, 54%), followed by 
      balanced products (76, 42%), and then delta-9-tetrahydrocannabinol (THC)-dominant 
      products (8, 4.4%). The most frequent AEs were dizziness (18.2%), nausea (9.1%), 
      dry mouth (9.1%), and tinnitus (9.1%). Significant reductions in ESAS-r scores 
      were observed over time in the domains of drowsiness (p = .013) and tiredness (p 
      = .031), but not pain (p = .106) or well-being (p = .274). Significant reductions 
      in BPI-SF scores over time were observed for worst pain (p = .010), average pain 
      (p = .012), and overall pain severity (p = 0.009), but not pain right now (p = 
      .052) or least pain (p = .141). CONCLUSIONS: Overall, results suggest medical 
      cannabis was safe, well-tolerated, and associated with clinically meaningful 
      reductions in pain in this sample of older adults. However, the potential bias 
      introduced by the high subject attrition rate means that all findings should be 
      interpreted cautiously and confirmed by more rigorous studies.
CI  - (c) 2022. The Author(s).
FAU - MacNair, Laura
AU  - MacNair L
AD  - Canopy Growth Corporation, Toronto, Ontario, Canada.
FAU - Kalaba, Maja
AU  - Kalaba M
AUID- ORCID: 0000-0002-3628-5197
AD  - Canopy Growth Corporation, Toronto, Ontario, Canada. 
      maja.kalaba@canopygrowth.com.
FAU - Peters, Erica N
AU  - Peters EN
AD  - Canopy Growth Corporation, Toronto, Ontario, Canada.
FAU - Feldner, Matthew T
AU  - Feldner MT
AD  - Canopy Growth Corporation, Toronto, Ontario, Canada.
FAU - Eglit, Graham M L
AU  - Eglit GML
AD  - Canopy Growth Corporation, Toronto, Ontario, Canada.
FAU - Rapin, Lucile
AU  - Rapin L
AD  - Sante Cannabis, Quebec, Canada.
FAU - El Hage, Cynthia
AU  - El Hage C
AD  - Sante Cannabis, Quebec, Canada.
FAU - Prosk, Erin
AU  - Prosk E
AD  - Sante Cannabis, Quebec, Canada.
FAU - Ware, Mark A
AU  - Ware MA
AD  - Canopy Growth Corporation, Toronto, Ontario, Canada.
LA  - eng
PT  - Journal Article
DEP - 20220922
PL  - England
TA  - J Cannabis Res
JT  - Journal of cannabis research
JID - 101752723
PMC - PMC9494878
OTO - NOTNLM
OT  - Medical cannabis
OT  - Older adults
OT  - Pain
OT  - Safety
COIS- L.R., C.E., and E.P. from Sante Cannabis were involved in the design and conduct 
      of the study. L.M., M.K., E.N.P., M.T.F., G.M.L.E., and M.A.W. from Canopy Growth 
      were involved in the analysis of the data and writing of the manuscript. Both 
      were involved in the decision to publish findings. L.M., M.K., E.N.P., M.T.F., 
      G.M.L.E, and M.A.W. are employees of Canopy Growth Corporation. L.R., C.E., and 
      E.P. are employees of Sante Cannabis. No other owners, officers, or employees of 
      Sante Cannabis or Canopy Growth played any role in the design or conduct of the 
      study, analysis of the data, writing of the manuscript, or the decision to 
      publish.
EDAT- 2022/09/22 06:00
MHDA- 2022/09/22 06:01
PMCR- 2022/09/22
CRDT- 2022/09/21 23:41
PHST- 2021/10/25 00:00 [received]
PHST- 2022/08/09 00:00 [accepted]
PHST- 2022/09/21 23:41 [entrez]
PHST- 2022/09/22 06:00 [pubmed]
PHST- 2022/09/22 06:01 [medline]
PHST- 2022/09/22 00:00 [pmc-release]
AID - 10.1186/s42238-022-00158-5 [pii]
AID - 158 [pii]
AID - 10.1186/s42238-022-00158-5 [doi]
PST - epublish
SO  - J Cannabis Res. 2022 Sep 22;4(1):50. doi: 10.1186/s42238-022-00158-5.